Gateway 2012: Rommelag - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2012: Rommelag



Your online Gateway to Rommelag in 2012

27905 Meadow Dr., Suite 9
PO Box 2530
Evergreen, CO  80437
303-674-8333
303-670-2666
www.rommelag.com

Don't miss Rommelag at Interphex 2012, May 1–3, Javits Center, New York, N.Y.

About Rommelag

Rommelag custom designs and builds blow/fill/seal machines for advanced aseptic liquid packaging. We serve the pharmaceutical, healthcare, cosmetic and chemical industries. Applications start at 0.1 mL. Packages such as ampoules, vials, bags, bottles, bellows, are all formed, filled, and sealed in one cycle on one machine. This year we are once again a featured company in the Advanced Aseptic Technologies Tour, register at www.interphex.com/Register.

Visit our Booth: # 2617, contact mail@rommelag.com to set an appointment time during the show.

Rommelag® representatives will be at Interphex 2012 to talk with your organization about the advantages of the Blow-Fill-Seal process for all your Advanced Aseptic liquid packaging needs. The Blow-Fill-Seal process is a fully automated Advance Aseptic system for producing Large Volume Parenteral (LVP) and Small Volume Parenteral (SVP) products. Pharmaceutical companies worldwide are switching from glass ampoules and bottles to the durable, lightweight, plastic bottles formed with the Blow–Fill–Seal process. rommelag® has been providing the industry with superior quality machines and support for over 40 years.

 

 

 



ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here